Novo Nordisk, a Danish drugmaker, has taken its fight to the Delhi High Court to stop two Indian companies, Sun Pharma and Alkem Laboratories, from making or selling a key ingredient called semaglutide. This ingredient is used in Novo Nordisk's popular drug Wegovy, which helps treat Type 2 diabetes and obesity.
The case is part of a larger legal battle over who can make and sell semaglutide, one of the world's most in-demand GLP-1 drugs. Novo Nordisk has two important patents in India that protect its semaglutide products. One patent, which covered the basic composition of semaglutide, expired in September 2024. However, another patent, which covers specific formulations and delivery devices, is still valid until March 2026.
Now that the basic composition patent has expired, many Indian pharmaceutical companies, including Sun Pharma, want to enter the GLP-1 segment. This market has seen significant growth globally due to the high demand for weight-loss therapies. Dr. Reddy's Laboratories (DRL) is already allowed to make and export its version of semaglutide, but it cannot sell it in India until Novo Nordisk's patent expires.
The outcome of this case will determine whether Indian drugmakers can start selling their versions of semaglutide before the patent on formulations expires in 2026. This could be a significant development for India's fast-growing obesity and diabetes drug market. The case is being closely watched and could set a precedent for generic drugs entering this market.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram